Yield10 Bioscience Inc
Yield10 Bioscience, Inc. operates as an agricultural bioscience company that focuses on commercializing products using the Camelina oilseeds in the United States. Its products include Camelina oil for production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA); and for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, … Read more
Yield10 Bioscience Inc (YTEN) - Total Assets
Latest total assets as of June 2024: $2.97 Million USD
Based on the latest financial reports, Yield10 Bioscience Inc (YTEN) holds total assets worth $2.97 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Yield10 Bioscience Inc - Total Assets Trend (2002–2023)
This chart illustrates how Yield10 Bioscience Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Yield10 Bioscience Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Yield10 Bioscience Inc's total assets of $2.97 Million consist of 35.8% current assets and 64.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 27.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2002–2023)
This chart illustrates how Yield10 Bioscience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Yield10 Bioscience Inc's current assets represent 35.8% of total assets in 2023, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 27.3% of total assets in 2023, up from 0.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Yield10 Bioscience Inc Competitors by Total Assets
Key competitors of Yield10 Bioscience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥6.84 Billion |
|
ADAMA Ltd
SHE:000553
|
China | CN¥49.93 Billion |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥8.43 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
China | CN¥50.97 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥5.17 Billion |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
China | CN¥19.38 Billion |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥19.75 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥9.46 Billion |
Yield10 Bioscience Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Yield10 Bioscience Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Yield10 Bioscience Inc is currently not profitable relative to its asset base.
Yield10 Bioscience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.16 | 1.22 | 1.99 |
| Quick Ratio | 0.16 | 1.22 | 1.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.46 Million | $ 555.00K | $ 1.75 Million |
Yield10 Bioscience Inc - Advanced Valuation Insights
This section examines the relationship between Yield10 Bioscience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 11.23 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -51.7% |
| Total Assets | $3.91 Million |
| Market Capitalization | $8.06K USD |
Valuation Analysis
Below Book Valuation: The market values Yield10 Bioscience Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Yield10 Bioscience Inc's assets decreased by 51.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Yield10 Bioscience Inc (2002–2023)
The table below shows the annual total assets of Yield10 Bioscience Inc from 2002 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $3.91 Million | -51.68% |
| 2022-12-31 | $8.09 Million | -60.40% |
| 2021-12-31 | $20.41 Million | +40.58% |
| 2020-12-31 | $14.52 Million | -13.14% |
| 2019-12-31 | $16.72 Million | +29.00% |
| 2018-12-31 | $12.96 Million | -23.23% |
| 2017-12-31 | $16.88 Million | +57.07% |
| 2016-12-31 | $10.75 Million | -37.10% |
| 2015-12-31 | $17.09 Million | -26.14% |
| 2014-12-31 | $23.14 Million | -13.48% |
| 2013-12-31 | $26.74 Million | -50.03% |
| 2012-12-31 | $53.51 Million | -35.46% |
| 2011-12-31 | $82.91 Million | +24.17% |
| 2010-12-31 | $66.77 Million | -31.55% |
| 2009-12-31 | $97.55 Million | +0.63% |
| 2008-12-31 | $96.95 Million | -18.54% |
| 2007-12-31 | $119.00 Million | -6.73% |
| 2006-12-31 | $127.60 Million | +1642.02% |
| 2005-12-31 | $7.32 Million | -2.47% |
| 2004-12-31 | $7.51 Million | -129.80% |
| 2002-12-31 | $-25.20 Million | -- |